The Valley Desk

Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical OncologyPublished

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published
Subject terms
T-Lymphocytes; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Antineoplastic Agents; Antibodies, Bispecific; Ligands; Small Cell Lung Carcinoma
PubMed ID
36689692
PubMed Central ID
PMC10414718
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal